In recent weeks, European markets have shown resilience, with the pan-European STOXX Europe 600 Index remaining stable as investors navigate interest rate policies and trade tensions. As business activity in the eurozone reaches a 16-month high, attention turns to growth companies where high insider ownership can often signal strong confidence in future performance.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| XTPL (WSE:XTP) | 23.3% | 107.3% |
| Xbrane Biopharma (OM:XBRANE) | 13% | 112.0% |
| Pharma Mar (BME:PHM) | 11.9% | 44.2% |
| MedinCell (ENXTPA:MEDCL) | 12.5% | 90.7% |
| KebNi (OM:KEBNI B) | 36.3% | 63.7% |
| Elliptic Laboratories (OB:ELABS) | 24.4% | 97.5% |
| CTT Systems (OM:CTT) | 17.5% | 37.9% |
| Circus (XTRA:CA1) | 24.5% | 67.1% |
| CD Projekt (WSE:CDR) | 29.7% | 43.5% |
| Bonesupport Holding (OM:BONEX) | 10.4% | 59.4% |
Here we highlight a subset of our preferred stocks from the screener.
Pharma Mar (BME:PHM)
Simply Wall St Growth Rating: ★★★★★★
Overview: Pharma Mar, S.A. is a biopharmaceutical company that specializes in the research, development, production, and commercialization of bio-active principles for oncology across various international markets with a market cap of €1.61 billion.
Operations: Pharma Mar generates revenue through its focus on the research, development, production, and commercialization of bio-active oncology principles across Spain, Italy, Germany, Ireland, France, the rest of the European Union, the United States, and other international markets.
Insider Ownership: 11.9%
Earnings Growth Forecast: 44.2% p.a.
Pharma Mar demonstrates significant growth potential, with earnings forecasted to increase by 44.15% annually and revenue expected to grow at 27.3% per year, outpacing the Spanish market. The company recently reported a substantial rise in net income to €19.42 million for H1 2025 from €3.54 million the previous year, reflecting strong operational performance. Despite high share price volatility, Pharma Mar trades significantly below its estimated fair value, indicating possible undervaluation opportunities for investors interested in growth companies with high insider ownership.
- Unlock comprehensive insights into our analysis of Pharma Mar stock in this growth report.
- In light of our recent valuation report, it seems possible that Pharma Mar is trading behind its estimated value.
CVC Capital Partners (ENXTAM:CVC)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: CVC Capital Partners plc is a private equity and venture capital firm that focuses on middle market secondaries, infrastructure, credit, management buyouts, leveraged buyouts, growth equity, mature investments, recapitalizations, strip sales and spinouts with a market cap of €16.11 billion.
Operations: The firm's revenue is primarily derived from its Private Equity segment (€951.11 million), followed by Credit (€197.65 million) and Secondaries (€124.38 million).
Insider Ownership: 20.2%
Earnings Growth Forecast: 16.6% p.a.
CVC Capital Partners, recently added to the Amsterdam AEX Index, is exploring strategic acquisitions like a stake in Avendus Capital and La Trobe Financial. Despite not having significant insider buying or selling activity over the past three months, CVC's earnings grew 299.2% last year and are forecasted to grow by 16.57% annually, surpassing Dutch market averages. While trading slightly below its fair value estimate, CVC faces high debt levels but remains focused on expanding its investment portfolio strategically.
- Delve into the full analysis future growth report here for a deeper understanding of CVC Capital Partners.
- According our valuation report, there's an indication that CVC Capital Partners' share price might be on the expensive side.
Verve Group (XTRA:M8G)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Verve Group SE is a digital media company that provides ad-software solutions in North America and Europe, with a market cap of €459.86 million.
Operations: Verve Group SE generates revenue through its Demand Side Platforms (DSP), contributing €130.94 million, and Supply Side Platforms (SSP), accounting for €399.07 million.
Insider Ownership: 24.5%
Earnings Growth Forecast: 53.4% p.a.
Verve Group, with substantial insider ownership, faces challenges despite its growth potential. Recent earnings showed a decline in profit margins from 13.4% to 4.5%, and revenue guidance was lowered due to technical issues and FX impacts. However, earnings are forecasted to grow significantly at 53.4% annually, outpacing the German market's average of 16.5%. Although insider buying occurred recently, it wasn't substantial enough to offset volatility concerns or financial pressures from interest payments not being well covered by earnings.
- Click to explore a detailed breakdown of our findings in Verve Group's earnings growth report.
- The analysis detailed in our Verve Group valuation report hints at an deflated share price compared to its estimated value.
Next Steps
- Click this link to deep-dive into the 183 companies within our Fast Growing European Companies With High Insider Ownership screener.
- Searching for a Fresh Perspective? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Pharma Mar might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com